Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: a systematic review.

Tornesello ML, Buonaguro L, Buonaguro FM.

Gynecol Oncol. 2013 Mar;128(3):442-8. doi: 10.1016/j.ygyno.2012.11.017. Epub 2012 Nov 17. Review.

PMID:
23168175
2.

TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.

Tornesello ML, Annunziata C, Buonaguro L, Losito S, Greggi S, Buonaguro FM.

J Transl Med. 2014 Sep 16;12:255. doi: 10.1186/s12967-014-0255-5.

3.
4.

Human papillomavirus infection and TP53 gene mutation in primary cervical carcinoma.

Kim JW, Cho YH, Lee CG, Kim JH, Kim HK, Kim EJ, Han KT, Namkoong SE.

Acta Oncol. 1997;36(3):295-300.

PMID:
9208900
5.

High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.

Gonzalez-Zulueta M, Shibata A, Ohneseit PF, Spruck CH 3rd, Busch C, Shamaa M, El-Baz M, Nichols PW, Gonzalgo ML, Elbaz M [corrected to El-Baz M], et al.

J Natl Cancer Inst. 1995 Sep 20;87(18):1383-93. Erratum in: J Natl Cancer Inst 1995 Dec 6;87(23):1807.

PMID:
7658499
6.

Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection.

Fujita M, Inoue M, Tanizawa O, Iwamoto S, Enomoto T.

Cancer Res. 1992 Oct 1;52(19):5323-8.

7.

Altered expression of nm23-H1 and c-erbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix.

Mandai M, Konishi I, Koshiyama M, Komatsu T, Yamamoto S, Nanbu K, Mori T, Fukumoto M.

Cancer. 1995 May 15;75(10):2523-9.

8.

Differentiated vulvar intraepithelial neoplasia contains Tp53 mutations and is genetically linked to vulvar squamous cell carcinoma.

Pinto AP, Miron A, Yassin Y, Monte N, Woo TY, Mehra KK, Medeiros F, Crum CP.

Mod Pathol. 2010 Mar;23(3):404-12. doi: 10.1038/modpathol.2009.179. Epub 2010 Jan 8.

9.

Mutation of tumor suppressor gene p53 is frequently found in vulvar carcinoma cells.

Hietanen SH, Kurvinen K, Syrjänen K, Grénman S, Carey T, McClatchey K, Syrjänen S.

Am J Obstet Gynecol. 1995 Nov;173(5):1477-82.

PMID:
7503188
10.

Analysis and clinical implications of p53 gene mutations and human papillomavirus type 16 and 18 infection in primary adenocarcinoma of the uterine cervix.

Tenti P, Pavanello S, Padovan L, Spinillo A, Vesentini N, Zappatore R, Migliora P, Zara C, Ranzani GN, Carnevali L.

Am J Pathol. 1998 Apr;152(4):1057-63.

11.

Tumor hypoxia, p53, and prognosis in cervical cancers.

Haensgen G, Krause U, Becker A, Stadler P, Lautenschlaeger C, Wohlrab W, Rath FW, Molls M, Dunst J.

Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):865-72.

PMID:
11429213
12.

Longitudinal study of TP53 mutations in eight patients with potentially malignant oral mucosal disorders.

Ogmundsdóttir HM, Hilmarsdóttir H, Björnsson J, Holbrook WP.

J Oral Pathol Med. 2009 Oct;38(9):716-21. doi: 10.1111/j.1600-0714.2009.00767.x. Epub 2009 Mar 14.

PMID:
19473449
13.

Relationship between TP53 tumour suppressor gene mutations and smoking-related bulky DNA adducts in a lung cancer study population from Hungary.

Anna L, Holmila R, Kovács K, Gyorffy E, Gyori Z, Segesdi J, Minárovits J, Soltész I, Kostic S, Csekeo A, Husgafvel-Pursiainen K, Schoket B.

Mutagenesis. 2009 Nov;24(6):475-80. doi: 10.1093/mutage/gep031. Epub 2009 Jul 30.

PMID:
19643813
14.

Frequent inactivation of the TP53 gene in esophageal squamous cell carcinoma from a high-risk population in China.

Hu N, Huang J, Emmert-Buck MR, Tang ZZ, Roth MJ, Wang C, Dawsey SM, Li G, Li WJ, Wang QH, Han XY, Ding T, Giffen C, Goldstein AM, Taylor PR.

Clin Cancer Res. 2001 Apr;7(4):883-91.

15.

Elderly Japanese women with cervical carcinoma show higher proportions of both intermediate-risk human papillomavirus types and p53 mutations.

Nakagawa S, Yoshikawa H, Jimbo H, Onda T, Yasugi T, Matsumoto K, Kino N, Kawana K, Kozuka T, Nakagawa K, Aoki M, Taketani Y.

Br J Cancer. 1999 Mar;79(7-8):1139-44.

16.

Molecular analysis of ras oncogenes in CIN III and in stage I and II invasive squamous cell carcinoma of the uterine cervix.

O'Leary JJ, Landers RJ, Silva I, Uhlmann V, Crowley M, Healy I, Luttich K.

J Clin Pathol. 1998 Aug;51(8):576-82.

17.

Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma.

Kang S, Kim HS, Seo SS, Park SY, Sidransky D, Dong SM.

Gynecol Oncol. 2007 Jun;105(3):662-6. Epub 2007 Mar 13.

PMID:
17360030
18.

Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.

Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P, Hrstka R, Janotova P, Radina M, Lane DP, Coates PJ, Vojtesek B.

J Pathol. 2005 Nov;207(3):251-9.

PMID:
16161005
19.

TP53 mutation pattern of esophageal squamous cell carcinomas in a high risk area (Southern Brazil): role of life style factors.

Pütz A, Hartmann AA, Fontes PR, Alexandre CO, Silveira DA, Klug SJ, Rabes HM.

Int J Cancer. 2002 Mar 1;98(1):99-105.

20.

[p53 protein in patients with Figo stage III cervix cancer].

Kainz C, Gitsch G, Joura E, Breitenecker G.

Gynakol Geburtshilfliche Rundsch. 1992;32 Suppl 1:116. German. No abstract available.

PMID:
1286309

Supplemental Content

Support Center